Products for Research Use Only
RegisterLogin

Altiratinib

CAT: 0013-GTR19172492-03Size: 10 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0013-GTR19172492-03Size:10 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Altiratinib (DCC-2701) is a multi-kinase inhibitor targeting c-MET, TIE-2, and VEGFR. It has been shown to inhibit c-MET phosphorylation, cell proliferation, and migration in vitro, and demonstrates efficacy in reducing tumor growth in vivo, supporting its investigation in oncology research.
CAS Number
1345847-93-9
Product Name Alternative
Tie2, Tie-2, Trkreceptor, Tropomyosin related kinase receptor, Trk receptor, Trk Receptor, TrkA, TrkC, Vascular endothelial growth factor receptor, VEGFR, Inhibitor, HGFR, Fms like tyrosine kinase 3, FLT3, inhibit, DCC2701, DCC-2701, DCC 2701, c-Met/HGFR, cMet, c-Met, cMet/HGFR, Cluster of differentiation antigen 135, CD135, Altiratinib
Field of Research
Cardiovascular Research, Signal Transduction
Purity
98.98% (May vary between batches)
Solubility
10% DMSO+40% PEG300+5% Tween 80+45% Saline:2 mg/mL (3.92 mM) ; DMSO:240 mg/mL (470.16 mM)
Smiles
Fc1ccc (NC (=O) C2 (CC2) C (=O) Nc2cc (F) c (Oc3ccnc (NC (=O) C4CC4) c3) cc2F) cc1
Molecular Formula
C26H21F3N4O4
Molecular Weight
510.46
Storage Conditions
-20°C
Notes
For research use only.

Chemical Information

Altiratinib

Altiratinib is an orally bioavailable inhibitor of c-Met/hepatocyte growth factor receptor (HGFR), vascular endothelial growth factor receptor type 2 (VEGFR2), Tie2 receptor tyrosine kinase (TIE2), and tropomyosin receptor kinase (Trk), with potential antiangiogenic and antineoplastic activities. Upon administration, altiratinib selectively binds to c-Met, VEGFR2, Tie2 and Trk tyrosine kinases, which may lead to the inhibition of endothelial cell migration, proliferation and survival. This also results in both an inhibition of tumor cell proliferation and increased tumor cell death in c-Met/VEGFR2/Tie2/Trk-expressing cells. These receptor tyrosine kinases (RTKs), frequently overexpressed or mutated by a variety of tumor cell types, play crucial roles in the regulation of angiogenesis, tumor cell growth and survival.

CAS Number1345847-93-9
PubChem CID54576299
IUPAC Name1-N'-[4-[[2-(cyclopropanecarbonylamino)-4-pyridinyl]oxy]-2,5-difluorophenyl]-1-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
Molecular FormulaC26H21F3N4O4
Molecular Weight510.5
XLogP4.3
Topological Polar Surface Area109
Hydrogen Bond Donor Count3
Hydrogen Bond Acceptor Count8
Rotatable Bond Count8
Heavy Atom Count37
Formal Charge0
Complexity863
SMILES
C1CC1C(=O)NC2=NC=CC(=C2)OC3=C(C=C(C(=C3)F)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F)F
InChI
InChI=1S/C26H21F3N4O4/c27-15-3-5-16(6-4-15)31-24(35)26(8-9-26)25(36)32-20-12-19(29)21(13-18(20)28)37-17-7-10-30-22(11-17)33-23(34)14-1-2-14/h3-7,10-14H,1-2,8-9H2,(H,31,35)(H,32,36)(H,30,33,34)
InChIKey
GNNDEPIMDAZHRQ-UHFFFAOYSA-N
Chemical Structure
2D Structure
2D structure of Altiratinib
CAS: 1345847-93-9
CID: 54576299
Formula: C26H21F3N4O4
MW: 510.5
Interactive 3D Structure
Loading 3D structure...
View on PubChemRaw 3D data
Computed Properties
PropertyValue
Molecular Weight510.5
XLogP34.3
Hydrogen Bond Donor Count3
Hydrogen Bond Acceptor Count8
Rotatable Bond Count8
Exact Mass510.15148965
Monoisotopic Mass510.15148965
Topological Polar Surface Area109 Ų
Heavy Atom Count37
Formal Charge0
Complexity863
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently-Bonded Unit Count1
Compound Is CanonicalizedYes

Alternative Products

CatalogName
T2054-01Altiratinib
MBS3840338-01Altiratinib (DCC2701)
MBS575617Altiratinib(DCC2701)
A14387-5Altiratinib 5mg
A14387-25Altiratinib 25mg
A14387-10Altiratinib 10mg
MBS130772-01Altiratinib(DCC-2701)
A14387-100Altiratinib (DCC2701) 100mg
A14387-50Altiratinib (DCC2701) 50mg

Popular Products